PZA Innovation was founded with the core mission of developing reliable tuberculosis drugs through innovative methods such as reverse engineering and in-vivo sterilization. The company focuses on addressing the global challenge of pyrazinamide (PZA)-resistant tuberculosis by creating accurate and reliable PZA susceptibility tests. Their work aims to improve clinical outcomes for the millions of new PZA-resistant TB cases annually by ensuring that PZA can effectively shorten the treatment duration from 9-12 months to 6 months.

Notable affiliated individuals and investors include experts in microbiology and pharmacology, though specific names are not provided. Key achievements of PZA Innovation include pioneering a method to determine the conditions under which pyrazinamide is active in vitro, thereby enhancing its efficacy in vivo. The overall impact of their work is significant, as it addresses a critical gap in tuberculosis treatment and has the potential to improve patient outcomes globally by ensuring more effective use of existing drugs.